The quick answer

Ozempic and Wegovy are the same medication. Both are semaglutide, made by Novo Nordisk, injected once weekly. The differences come down to FDA approval, dosing, and insurance coverage.

Wegovy goes up to 2.4mg and is FDA-approved specifically for chronic weight management. Ozempic maxes out at 2mg and is approved for type 2 diabetes. That extra 0.4mg matters for weight loss results.

If your primary goal is losing weight and you can get Wegovy covered by insurance (or you’re paying cash), Wegovy is the better choice. If you have type 2 diabetes and need insurance coverage, Ozempic is often the practical option since insurers cover it more readily.

Either way, you’re getting semaglutide. The question is which dose and which insurance pathway works for your situation.

Key differences at a glance

What the clinical trials showed

Both Ozempic and Wegovy have been studied extensively, but in different trials for different purposes. Understanding these trials helps explain why weight loss results differ.

SUSTAIN trials (Ozempic)

The SUSTAIN program tested Ozempic primarily for blood sugar control in people with type 2 diabetes. Weight loss was a secondary outcome. Key findings:

• → SUSTAIN-1: 3.7% weight loss at 0.5mg, 4.5% at 1mg over 30 weeks
• → SUSTAIN-2: 4.3% weight loss at 0.5mg, 6.1% at 1mg over 56 weeks
• → SUSTAIN-6: Showed 26% reduction in major cardiovascular events

These trials used diabetes-focused doses (0.5mg and 1mg primarily). The 2mg dose wasn’t tested until later studies.

STEP trials (Wegovy)

The STEP program tested semaglutide 2.4mg specifically for weight loss in people with obesity (with or without diabetes). Results were substantially better:

• → STEP-1: 14.9% weight loss at 68 weeks (vs 2.4% placebo)
• → STEP-2 (diabetics): 9.6% weight loss at 68 weeks
• → STEP-3 (with intensive behavioral therapy): 16% weight loss
• → STEP-4 (withdrawal study): Weight regain of 6.9% after stopping

The STEP trials established that higher-dose semaglutide (2.4mg) produces significantly more weight loss than diabetes doses. This is why Wegovy is the preferred choice when weight loss is the primary goal.

Real-world data

Clinical trials have strict inclusion criteria and close monitoring. Real-world results are often slightly lower but still substantial:

A 2025 retrospective study of over 18,000 patients found Wegovy users lost an average of 5.9% of body weight at 6 months compared to 3.6% for Ozempic users at equivalent time points. The higher dose matters.

Weight loss comparison by timepoint

The higher dose in Wegovy produces more weight loss at every timepoint:

For a 200 lb person, that difference translates to:

• → Ozempic at 12 months: 20-28 lbs lost
• → Wegovy at 12 months: 30-34 lbs lost
• → Difference: 6-10 additional pounds with Wegovy

Both are effective. But if you’re choosing between them and have equal access, Wegovy delivers more.

Cardiovascular benefits

Both Ozempic and Wegovy have proven benefits for heart health. This is important because obesity and diabetes both increase cardiovascular risk.

The SELECT trial

The SELECT trial (2023) was a landmark study that tested semaglutide 2.4mg (Wegovy dose) in over 17,000 adults with obesity and established cardiovascular disease but without diabetes. Results:

• → 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death)
• → Benefits appeared within the first year and persisted throughout the study
• → Effects were independent of weight loss (though weight loss likely contributed)

This trial led to Wegovy receiving FDA approval for cardiovascular risk reduction in March 2024, making it the first weight loss medication with this indication.

What this means for you

If you have existing heart disease, obesity, or high cardiovascular risk, semaglutide offers benefits beyond weight loss. Both Ozempic and Wegovy provide this protection, though Wegovy was the dose specifically studied in SELECT.

Side effects comparison

Since Ozempic and Wegovy contain the same active ingredient, their side effects are identical. The main difference is that Wegovy’s higher dose may cause slightly more intense GI symptoms initially.

Common side effects (both medications)

Both medications use gradual dose titration specifically to minimize these side effects. Starting at 0.25mg and slowly increasing gives your body time to adjust. Most people find the GI symptoms manageable and improving over time.

Serious side effects (rare, both medications)

• → Pancreatitis: Inflammation of the pancreas. Stop the medication and seek care if you have severe abdominal pain.
• → Gallbladder problems: Rapid weight loss can trigger gallstones. More common at higher doses.
• → Thyroid tumors: Boxed warning based on rodent studies. Not confirmed in humans but avoid if you have personal or family history of medullary thyroid carcinoma.
• → Hypoglycemia: Mainly a concern if combined with insulin or sulfonylureas.

Dose-related differences

Because Wegovy goes to 2.4mg while Ozempic maxes at 2mg, some people experience slightly more GI issues on Wegovy at full dose. However, the slow titration schedule (5 months to reach 2.4mg) helps minimize this. The STEP trials showed dropout rates due to side effects were similar between doses.

Dosing schedules compared

Both medications use slow titration to minimize side effects, but the schedules differ because Wegovy reaches a higher final dose.

Wegovy has two additional dose steps (1.7mg and 2.4mg) that don’t exist for Ozempic. This means Wegovy takes about twice as long to reach maximum dose, but the gradual approach helps your body adjust to the higher levels.

Cost and insurance coverage

Cost is often the deciding factor between Ozempic and Wegovy, especially since insurance coverage differs significantly.

List prices (without insurance)

The insurance problem

Insurance coverage is where these two medications diverge significantly:

Ozempic for diabetes: Most commercial insurers cover Ozempic for type 2 diabetes with prior authorization. You’ll need A1C documentation showing you have diabetes, and possibly evidence that you’ve tried metformin first. Once approved, copays are typically $25-150/month.

Wegovy for weight loss: Coverage is inconsistent. Many insurance plans explicitly exclude weight loss medications in their formularies. Others cover Wegovy but require:

• → BMI ≥30, or BMI ≥27 with a weight-related condition
• → Documentation of failed diet/exercise attempts
• → Prior authorization and sometimes step therapy
• → Ongoing proof of weight loss to continue coverage

Medicare: Medicare Part D does not cover weight loss medications by law. This affects millions of older adults who might benefit from Wegovy. Ozempic is covered for diabetes but cannot be prescribed off-label for weight loss under Medicare.

Prior authorization tips

If you’re trying to get coverage for either medication:

• → Document your BMI, weight-related conditions, and previous weight loss attempts
• → Have your provider write a detailed letter of medical necessity
• → If denied, appeal. Many initial denials are overturned on appeal
• → Check if your plan has any obesity treatment benefits separate from pharmacy benefits

Compounded semaglutide: A third option

If neither brand-name option works for your budget or insurance situation, compounded semaglutide offers the same active ingredient at a fraction of the cost.

What is compounded semaglutide?

Compounding pharmacies prepare semaglutide from bulk pharmaceutical ingredients. During FDA-recognized drug shortages (which have been ongoing), this is legal. The resulting medication contains the same active ingredient as Ozempic and Wegovy.

Cost comparison

The savings are substantial: $800-1,100 per month compared to brand-name options.

Considerations

• → Quality varies by pharmacy. Choose providers that use 503B-registered facilities
• → Not available through traditional pharmacies or covered by insurance
• → Requires medical oversight through telehealth or your own provider
• → If FDA shortage designation ends, availability may change

For many people paying out-of-pocket, compounded semaglutide is the practical choice. See our provider reviews for telehealth options that offer compounded semaglutide with proper medical supervision.

Which should you choose?

If you can only get Ozempic

Ask your provider about the 2mg dose. Most diabetes prescribing uses 0.5mg or 1mg, but the 2mg dose exists and provides results closer to Wegovy. It’s not quite the same as 2.4mg, but it’s better than stopping at 1mg.

Consider compounded semaglutide if:

• → You’re paying out-of-pocket
• → Insurance doesn’t cover either brand-name option
• → Cost is a significant barrier
• → You’re comfortable with telehealth supervision

Looking for alternatives?

Tirzepatide (Mounjaro/Zepbound) produces even more weight loss than semaglutide. If you’re considering your options, it’s worth discussing with your provider.

Frequently asked questions